JOP20190084A1 - ربائط إنتجرين ألفا- v بيتا-? واستخداماتها - Google Patents

ربائط إنتجرين ألفا- v بيتا-? واستخداماتها

Info

Publication number
JOP20190084A1
JOP20190084A1 JOP/2019/0084A JOP20190084A JOP20190084A1 JO P20190084 A1 JOP20190084 A1 JO P20190084A1 JO P20190084 A JOP20190084 A JO P20190084A JO P20190084 A1 JOP20190084 A1 JO P20190084A1
Authority
JO
Jordan
Prior art keywords
beta
alpha
integrin ligands
integrin
ligands
Prior art date
Application number
JOP/2019/0084A
Other languages
English (en)
Inventor
Matthew Fowler-Watters
Zhen Li
Aaron Almeida
Erik W Bush
Jeffrey Carlson
Anthony Nicholas
Tao Pei
Angieszka Glebocka
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of JOP20190084A1 publication Critical patent/JOP20190084A1/ar
Application granted granted Critical
Publication of JOP20190084B1 publication Critical patent/JOP20190084B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

<strong>يتعلق الاختراع الحالي بوصف مركبات ترابطية إنتجرين ذات ثبات في المصل وألفة لمركبات ترابطية </strong>αvβ6<strong>.</strong> <strong>ويتم أيضًا وصف التركيبات التي تشتمل على مركبات ترابطية لإنتجرين </strong>αvβ6<strong> ذات ثبات في المصل وألفة للمركبات الترابطية </strong>αvβ6<strong> وطرق استخدامها</strong>
JOP/2019/0084A 2016-11-01 2017-11-01 ربائط إنتجرين ألفا- v بيتا-6 واستخداماتها JOP20190084B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415752P 2016-11-01 2016-11-01
PCT/US2017/059550 WO2018085415A1 (en) 2016-11-01 2017-11-01 Alpha-v beta-6 integrin ligands and uses thereof

Publications (2)

Publication Number Publication Date
JOP20190084A1 true JOP20190084A1 (ar) 2019-04-16
JOP20190084B1 JOP20190084B1 (ar) 2023-09-17

Family

ID=62076333

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0084A JOP20190084B1 (ar) 2016-11-01 2017-11-01 ربائط إنتجرين ألفا- v بيتا-6 واستخداماتها

Country Status (21)

Country Link
US (2) US11180529B2 (ar)
EP (2) EP3981780A1 (ar)
JP (2) JP7291624B2 (ar)
KR (1) KR102634762B1 (ar)
CN (2) CN117285626A (ar)
AU (2) AU2017354041B2 (ar)
BR (1) BR112019008965A2 (ar)
CA (1) CA3039618A1 (ar)
DK (1) DK3535397T3 (ar)
EA (1) EA201991102A1 (ar)
ES (1) ES2906109T3 (ar)
HR (1) HRP20220181T1 (ar)
IL (2) IL305158A (ar)
JO (1) JOP20190084B1 (ar)
MX (3) MX2019004909A (ar)
PL (1) PL3535397T3 (ar)
SA (1) SA519401709B1 (ar)
SI (1) SI3535397T1 (ar)
TW (1) TWI776821B (ar)
WO (1) WO2018085415A1 (ar)
ZA (1) ZA201901905B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102634762B1 (ko) * 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
AU2018229275B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3649240A4 (en) 2017-07-06 2021-07-07 Arrowhead Pharmaceuticals, Inc. RNAI ALPHA-ENaC GENE EXPRESSION INHIBITION AGENTS AND METHODS OF USE
TW202035400A (zh) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素
KR102663798B1 (ko) 2019-06-25 2024-05-03 주식회사 엘지에너지솔루션 배터리 시스템
TW202227627A (zh) 2020-09-11 2022-07-16 美商愛羅海德製藥公司 用於抑制DUX4表現之RNAi藥劑、其組合物及使用方法
JP2023541427A (ja) * 2020-09-11 2023-10-02 アローヘッド ファーマシューティカルズ インコーポレイテッド 骨格筋送達プラットフォーム及び使用方法
CA3189081A1 (en) * 2020-09-11 2022-03-17 Xiaokai Li Integrin targeting ligands and uses thereof
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
EP1274730A2 (en) * 2000-04-21 2003-01-15 Amgen, Inc. Integrin/adhesion antagonists
DE10118550A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
CA2658612C (en) * 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
JP5497449B2 (ja) 2007-11-28 2014-05-21 富士フイルム株式会社 生体高分子およびポリペプチドの化学修飾方法
KR101782790B1 (ko) * 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
US9493566B2 (en) * 2012-02-17 2016-11-15 Seattle Genetics, Inc. Antibodies to integrin AVB6 and use of same to treat cancer
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US10073109B2 (en) 2015-04-06 2018-09-11 The Board Of Regents Of The University Of Oklahoma Phages of biomarker capture and methods of use
EP3130912B1 (de) 2015-08-14 2017-06-28 Sick Ag Verfahren zur bestimmung der konzentration einer gaskomponente und spektrometer dafür
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102634762B1 (ko) * 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도

Also Published As

Publication number Publication date
BR112019008965A2 (pt) 2019-07-09
AU2017354041B2 (en) 2024-02-01
ZA201901905B (en) 2022-11-30
TWI776821B (zh) 2022-09-11
SA519401709B1 (ar) 2023-06-04
HRP20220181T1 (hr) 2022-04-29
CN109952376B (zh) 2023-09-05
US20220024975A1 (en) 2022-01-27
TW201829445A (zh) 2018-08-16
AU2024202695A1 (en) 2024-05-16
KR20190075937A (ko) 2019-07-01
US11180529B2 (en) 2021-11-23
MX2019004909A (es) 2019-08-12
US20190248832A1 (en) 2019-08-15
AU2017354041A1 (en) 2019-04-11
EA201991102A1 (ru) 2019-09-30
MX2023007046A (es) 2023-06-23
IL266343A (en) 2019-06-30
KR102634762B1 (ko) 2024-02-06
WO2018085415A1 (en) 2018-05-11
PL3535397T3 (pl) 2022-03-07
JP2023105046A (ja) 2023-07-28
EP3535397B1 (en) 2022-01-05
ES2906109T3 (es) 2022-04-13
IL305158A (en) 2023-10-01
DK3535397T3 (da) 2022-01-31
MX2023007051A (es) 2023-06-23
JP2019535685A (ja) 2019-12-12
JOP20190084B1 (ar) 2023-09-17
CN117285626A (zh) 2023-12-26
JP7291624B2 (ja) 2023-06-15
IL266343B1 (en) 2023-09-01
SI3535397T1 (sl) 2022-04-29
CA3039618A1 (en) 2018-05-11
EP3535397A1 (en) 2019-09-11
IL266343B2 (en) 2024-01-01
EP3981780A1 (en) 2022-04-13
CN109952376A (zh) 2019-06-28
EP3535397A4 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JOP20190084A1 (ar) ربائط إنتجرين ألفا- v بيتا-? واستخداماتها
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
SG10201914126RA (en) Anti-ox40 antibodies and their uses
JOP20200074A1 (ar) أجسام مضادة ضد tau واستخداماتها
SG10201803042PA (en) Anti-tim-3 antibodies
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
WO2015015448A3 (en) Engineered polypeptide conjugates using transglutaminase
MX2019006334A (es) Anticuerpos antitau y métodos de uso.
MY188940A (en) Anti-pd-l1 antibodies and diagnostic uses thereof
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
WO2019094669A3 (en) Self-assembling protein structures and components thereof
WO2018029315A3 (en) Micropatterning assembly, methods for micropatterning, and micropatterned devices
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها